

Cohance Lifesciences injects Rs 23 Cr into cGMP oligonucleotide facility at Hyderabad

12 August 2025 | News

A high-impact strategic investment to complement pilot and scale-up assets



Cohance Lifesciences Limited, formerly Suven Pharmaceuticals, a partner of choice for global innovator pharma companies, has announced Rs 23 crore investment and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad.

This strategic investment strengthens the CRDMO's integrated oligonucleotide platform and enhances its position as a preferred partner for emerging modalities.

Cohance brings deep expertise in modified nucleosides and locked nucleic acids (LNA), with a proven track record in complex nucleoside and nucleic acid synthesis at the R&D stage. The new facility will enable the company to take these high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics.

Integrated with pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. This scale, combined with advanced environmental controls including ISO Class 8 clean rooms and RH-controlled areas, is designed to meet the stringent requirements of complex oligonucleotide building block production.

Customer engagements are already underway, with audits planned in the coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence in CY26.